Pulmonary Endothelium and Pulmonary Hypertension

The Pulmonary Endothelium: Function in health and disease

Volumn , Issue , 2009, Pages 449-460

  Tuder, Rubin M ^a   Erzurum, Serpil C ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Associated diseases of PAH (APAH); Chronic obstructive pulmonary diseases (COPDs); EC pathobiology novel concepts in pulmonary hypertension; Endothelium role in pulmonary hypertension and IPAH; Exuberant EC proliferation and misguided angiogenesis in pulmonary hypertension; HIV associated pulmonary hypertension; Human herpesvirus (HHV) 8 and proliferative switch of pulmonary ECs; Pulmonary endothelium and pulmonary hypertension; Vascular progenitor cells in pulmonary arteries

Indexed keywords

EID: 84873692204     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470747490.ch27     Document Type: Chapter

References (98)

1. Wright, J.L., Levy, R.D., and Churg, A. (2005) Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax, 60, 605-9.
2. Nathan, S.D., Noble, P.W., and Tuder, R.M. (2007) Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. American Journal of Respiratory and Critical Care Medicine, 175, 875-80.
3. Simonneau, G., Galie, N., Rubin, L.J. et al. (2004) Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology, 43, S5-S12.
4. Rubin, L.J. (1998) Primary pulmonary hypertension. Chest, 104, 236-50.
5. Mouthon, L., Guillevin, L., and Humbert, M. (2005) Pulmonary arterial hypertension: an autoimmune disease? European Respiratory Journal, 26, 986-88.
6. Loscalzo, J. (1992) Endothelial dysfunction in pulmonary hypertension. The New England Journal of Medicine, 327, 70-75.
7. Budhiraja, R., Tuder, R.M., and Hassoun, P.M. (2004) Endothelial dysfunction in pulmonary hypertension. Circulation, 109, 159-65.
8. Humbert, M., Sitbon, O., and Simonneau, G. (2004) Treatment of pulmonary arterial hypertension. The New England Journal of Medicine, 351, 1425-36.
9. Zaiman, A., Fijalkowska, I., Hassoun, P.M., and Tuder, R.M. (2005) One hundred years of research in the pathogenesis of pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology, 33, 425-31.
10. Tuder, R.M., Marecki, J.C., Richter, A. et al. (2007) Pathology of pulmonary hypertension. Clinics in Chest Medicine, 28, 23-42, vii.
11. Heath, D. and Edwards, J.E. (1958) The pathology of pulmonary hypertensive disease. A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal changes. Circulation, 18, 533-47.
12. Eddahibi, S., Morrell, N., d'Ortho, M.P. et al. (2002) Pathobiology of pulmonary arterial hypertension. European Respiratory Journal, 20, 1559-72.
13. Yamaki, S. and Wagenvoort, C.A. (1985) Comparison of primary plexogenic arteriopathy in adults and children. A morphometric study in 40 patients. British Heart Journal, 54, 428-34.
14. Tuder, R.M., Groves, B.M., Badesch, D.B., and Voelkel, N.F. (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. American Journal of Pathology, 144, 275-85.
15. Cool, C.D., Kennedy, D., Voelkel, N.F., and Tuder, R.M. (1997) Pathogenesis and evolution of plexi-form lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Human Pathology, 28, 434-42.
16. Cool, C.D., Stewart, J.S., Werahera, P. et al. (1999) Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. American Journal of Pathology, 155, 411-19.
17. Lee, S.D., Shroyer, K.R., Markham, N.E. et al. (1998) Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. The Journal of Clinical Investigation, 101, 927-34.
18. Tuder, R.M., Radisavljevic, Z., Shroyer, K.R. et al. (1998) Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 158, 1999-2001.
19. Tuder, R.M., Lee, S.D., and Cool, C.D. (1998) Histopathology of pulmonary hypertension. Chest, 114, 1S-6S.
20. Voelkel, N.F., Cool, C.D., Lee, S.D. et al. (1999) Primary pulmonary hypertension between inflammation and cancer. Chest, 114, 225S-230S.
21. Rai, P.R., Cool, C.D., King, J.A.C. et al. (2008) The cancer paradigm of severe pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 178, 558-64.
22. Yeager, M.E., Voelkel, N.F., and Tuder, R.M. (1999) Mutational analysis of endothelial cell TGF-β receptor type II in plexiform lesions of patients with primary pulmonary hypertension. Circulation, 100, I-587.
23. Yeager, M.E., Halley, G.R., Golpon, H.A. et al. (2001) Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circulation Research, 88, e8-e11.
24. Deng, Z., Morse, J.H., Slager, S.L. et al. (2000) Familial primary pulmonary hypertension (gene PPH1) Is caused by mutations in the bone morphogenetic protein receptor-II gene. American Journal of Human Genetics, 67, 737-44.
25. Lane, K.B., Machado, R.D., Pauciulo, M.W. et al. (2000) Heterozygous germline mutations in BMPR2 encoding a TGF-B receptor cause familiar pulmonary hypertension. Nature Genetics, 26, 81-84.
26. Tan, B.T., Park, C.Y., Ailles, L.E., and Weissman, I.L. (2006) The cancer stem cell hypothesis: a work in progress. Laboratory Investigation, 86, 1203-7.
27. Bull, T.M., Golpon, H., Hebbel, R.P. et al. (2003) Circulating endothelial cells in pulmonary hypertension. Thrombosis and Haemostasis, 90, 688-703.
28. Kasahara, Y., Tuder, R.M., Cool, C.D. et al. (2001) Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. American Journal of Respiratory and Critical Care Medicine, 163, 737-44.
29. Sakao, S., Taraseviciene-Stewart, L., Lee, J.D. et al. (2005) Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. The FASEB Journal, 19, 1178-180.
30. Taraseviciene-Stewart, L., Kasahara, Y., Alger, L. et al. (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. The FASEB Journal, 15, 427-38.
31. Tuder, R.M., Chacon, M., Alger, L.A. et al. (2001) Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angio-genesis. Journal of Pathology, 195, 367-74.
32. Machado, R.D., James, V., Southwood, M. et al. (2005) Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation, 111, 607-13.
33. Atkinson, C., Stewart, S., Upton, P.D. et al. (2002) Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation, 105, 1672-78.
34. Lowe, K., Alvarez, D., King, J., and Stevens, T. (2007) Phenotypic heterogeneity in lung capillary and extra-alveolar endothelial cells. Increased extra-alveolar endothelial permeability is sufficient to decrease compliance. The Journal ofSurgical Research, 143, 70-77.
35. Stevens, T., Kasper, M., Cool, C., and Voelkel, N.F. (2005) Pulmonary circulation and pulmonary hypertension, in Endothelial Cells in Health and Disease, 1st edn (ed. W.C. Aird), Taylor & Francis, Boca Raton, FL, pp. 417-38.
36. Ingram, D.A., Mead, L.E., Tanaka, H. et al. (2004) Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood, 104, 2752-60.
37. Yoder, M.C., Mead, L.E., Prater, D. et al. (2007) Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood, 109, 1801-9.
38. Xu, W., Kaneko, F.T., Zheng, S. et al. (2004) Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. The FASEB Journal, 18, 1746-48.
39. Masri, F.A., Xu, W., Comhair, S.A. et al. (2007) Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. American Journal of Physiology: Lung Cellular and Molecular Physiology, 293, L548-54.
40. Bartoli, M., Gu, X., Tsai, N.T. et al. (2000) Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. The Journal of Biological Chemistry, 275, 33189-92.
41. Niu, G., Wright, K.L., Huang, M. et al. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene, 21, 2000-8.
42. Shibata, R., Kai, H., Seki, Y. et al. (2003) Inhibition of STAT3 prevents neointima formation by inhibiting proliferation and promoting apoptosis of neointimal smooth muscle cells. Human Gene Therapy, 14, 601-10.
43. Yahata, Y., Shirakata, Y., Tokumaru, S. et al. (2003) Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. The Journal of Biological Chemistry, 278, 40026-31.
44. Xu, W., Koeck, T., Lara, A.R. et al. (2007) Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 104, 1342-47.
45. Sehgal, P.B. and Mukhopadhyay, S. (2007) Pulmonary arterial hypertension: a disease of tethers, SNAREs and SNAPs? American Journal of Physiology: Heart and Circulatory Physiology, 293, H77-85.
46. Mukhopadhyay, S., Shah, M., Xu, F. et al. (2007) Cytoplasmic provenance of STAT3 and PY-STAT3 in endolysosomal compartments in pulmonary arterial endothelial and smooth muscle cells: implications in PAH. American Journal of Physiology: Lung Cellular and Molecular Physiology, 294, L449-68.
47. Asosingh, K., Aldred, M.A., Vasanji, A. et al. (2008) Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. American Journal of Pathology, 172, 615-27.
48. Yuan, J.X., Aldinger, A.M., Juhaszova, M. et al. (1998) Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation, 98, 1400-6.
49. Krick, S., Platoshyn, O., McDaniel, S.S. et al. (2001) Augmented K+ currents and mitochondrial membrane depolarization in pulmonary artery myocyte apoptosis. American Journal of Physiology: Lung Cellular and Molecular Physiology, 281, L887-94.
50. McMurtry, M.S., Archer, S.L., Altieri, D.C., Bonnet, S. et al. (2005) Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. The Journal of Clinical Investigation, 115, 1479-91.
51. McMurtry, M.S., Bonnet, S., Wu, X. et al. (2004) Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circulation Research, 95, 830-40.
52. v channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats-similarities to human pulmonary arterial hypertension. Circulation, 113, 2630-41.
53. Archer, S. and Rich, S. (2000) Primary pulmonary hypertension: a vascular biology and translational research "work in progress". Circulation, 102, 2781-91.
54. Azeka, E., Costa, A.J. Jr., Kajita, L. et al. (2002) Effects of low doses of inhaled nitric oxide combined with oxygen for the evaluation of pulmonary vascular reactivity in patients with pulmonary hypertension. Pediatric Cardiology, 23, 20-26.
55. Champion, H.C., Bivalacqua, T.J., Greenberg, S.S. et al. (2002) Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 99, 13248-53.
56. Cooke, J.P. and Dzau, V.J. (1997) Nitric oxide synthase: role in the genesis of vascular disease. Annual Review ofMedicine, 48, 489-509.
57. Ignarro, L.J. (1993) Nitric oxide-mediated vasorelaxation. Thrombosis and Haemostasis, 70, 148-51.
58. Jeffery, T.K. and Morrell, N.W. (2002) Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Progress in Cardiovascular Diseases, 45, 173-202.
59. Kaneko, F.T., Arroliga, A.C., Dweik, R.A. et al. (1998) Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 158, 917-23.
60. Moncada, S. (1999) Nitric oxide: discovery and impact on clinical medicine. Journal of the Royal Society of Medicine, 92, 164-69.
61. Girgis, R.E., Champion, H.C., Diette, G.B. et al. (2005) Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. American Journal of Respiratory and Critical Care Medicine, 172, 352-57.
62. Ozkan, M., Dweik, R.A., Laskowski, D. et al. (2001) High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung, 179, 233-43.
63. Momken, I., Fortin, D., Serrurier, B. et al. (2002) Endothelial nitric oxide synthase (NOS) deficiency affects energy metabolism pattern in murine oxidative skeletal muscle. The Biochemical Journal, 368, 341-47.
64. Nisoli, E., Clementi, E., Paolucci, C. et al. (2003) Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science, 299, 896-99.
65. Nisoli, E., Falcone, S., Tonello, C. et al. (2004) Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proceedings of the National Academy of Sciences of the United States of America, 101, 16507-12.
66. Fagan, K.A., Fouty, B.W., Tyler, R.C. et al. (1998) The pulmonary circulation of mice with either homozygous or heterozygous disruption of endothelial nitric oxide synthase is hyperresponsive to chronic mild hypoxia. The Journal of Clinical Investigation, 1-3, 291-99.
67. Cawthon, D., Iqbal, M., Brand, J. et al. (2004) Investigation of proton conductance in liver mitochondria of broilers with pulmonary hypertension syndrome. Poultry Science, 83, 259-65.
68. Iqbal, M., Cawthon, D., Wideman, R.F., and Bottje, W.G. Jr. (2001) Lung mitochondrial dysfunction in pulmonary hypertension syndrome. I. Site-specific defects in the electron transport chain. Poultry Science, 80, 485-95.
69. Michelakis, E.D., McMurtry, M.S., Wu, X.C. et al. (2002) Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation, 105, 244-50.
70. Tang, Z., Iqbal, M., Cawthon, D., and Bottje, W.G. (2002) Heart and breast muscle mitochondrial dysfunction in pulmonary hypertension syndrome in broilers (Gallus domesticus). Comparative Biochemistry and Physiology, Part A: Molecular and Integrative Physiology, 132, 527-40.
71. Warburg, O., Posener, K., and Negelein, E. (1924) Ueber den stoffwechsel der carcinomzelle. Bio-chemische Zeitschrift, 152, 319-44.
72. Wang, T., Marquardt, C., and Foker, J. (1976) Aerobic glycolysis during lymphocyte proliferation. Nature, 261, 702-5.
73. Bonnet, S., Michelakis, E.D., Porter, C.J., ndrade-Navarro, M.A.,, Thebaud, B., Bonnet, S., Haromy, A., Harry, G., Moudgil, R., McMurtry, S., Weir, E.K. and Archer, S.L. (2006) An abnormal mitochondrial-hypoxia inducible factor-1 alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats-Similarities to human pulmonary arterial hypertension. Circulation, 113, 2630-2641.
74. Caslin, A.W., Heath, D., Madden, B. et al. (1990) The histopathology of 36 cases of plexogenic pulmonary arteriopathy. Histopathology, 16, 9-19.
75. Frid, M.G., Brunetti, J.A., Burke, D.L. et al. (2006) Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. American Journal of Pathology, 168, 659-69.
76. Smith, P. and Heath, D. (1979) Electron microscopy of the plexiform lesion. Thorax, 34, 177-86.
77. Stenmark, K.R., Fagan, K.A., and Frid, M.G. (2006) Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circulation Research, 99, 675-91.
78. Strieter, R.M., Gomperts, B.N., and Keane, M.P. (2007) The role of CXC chemokines in pulmonary fibrosis. The Journal of Clinical Investigation, 117, 549-56.
79. Gehling, U.M., Ergun, S., Schumacher, U. et al. (2000) In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood, 95, 3106-12.
80. Pesce, M., Orlandi, A., Iachininoto, M.G. et al. (2003) Myoendothelial differentiation of human umbilical cord blood-derived stem cells in ischemic limb tissues. Circulation Research, 93, e51-e62.
81. Prater, D.N., Case, J., Ingram, D.A., and Yoder, M.C. (2007) Working hypothesis to redefine endothelial progenitor cells. Leukemia, 21, 1141-49.
82. Hur, J., Yoon, C.H., Kim, H.S. et al. (2004) Characterization of two types of endothelial progenitor cells and their different contributions to neovasculo-genesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 288-93.
83. Ceradini, D.J., Kulkarni, A.R., Callaghan, M.J. et al. (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nature Medicine, 10, 858-64.
84. Davie, N.J., Crossno, J.T., Frid, M.G. et al. (2004) Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. American Journal of Physiology: Lung Cellular and Molecular Physiology, 286, L668-78.
85. Hayashida, K., Fujita, J., Miyake, Y. et al. (2005) Bone marrow-derived cells contribute to pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension. Chest, 127, 1793-98.
86. Cheng, X.W., Kuzuya, M., Nakamura, K. et al. (2007) Mechanisms underlying the impairment of ischemia-induced neovascularization in matrix metalloproteinase 2-deficient mice. Circulation Research, 100, 904-13.
87. Teichert-Kuliszewska, K., Kutryk, M.J., Kuliszewski, M.A. et al. (2006) Bone mor phogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circulation Research, 98, 209-17.
88. Peinado, V.I., Barbera, J.A., Ramirez, J. et al. (1998) Endothelial dysfunction in pulmonary arteries of patients with mild COPD. American Journal of Physiology: Lung Cellular and Molecular Physiology, 18, L908-13.
89. Eddahibi, S., Guignabert, C., Barlier-Mur, A.M. et al. (2006) Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation, 113, 1857-64.
90. Eddahibi, S., Humbert, M., Fadel, E. et al. (2001) Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. The Journal of Clinical Investigation, 108, 1141-50.
91. Grisotto, M.G., Garin, A., Martin, A.P. et al. (2006) The human herpesvirus 8 chemokine receptor vG-PCR triggers autonomous proliferation of endothelial cells. The Journal of Clinical Investigation, 116, 1264-73.
92. Cool, C.D., Rai, M.D., Yeager, M.E. et al. (2003) Expression of human herpesvirus 8 in primary pulmonary hypertension. The New England Journal of Medicine, 349, 1113-22.
93. Laney, A.S., De, M., Peters, J.S. et al. (2005) Kaposi sarcoma-associated herpesvirus and primary and secondary pulmonary hypertension. Chest, 127, 762-67.
94. Nicastri, E., Vizza, C.D., Carletti, F. et al. (2005) Human herpesvirus 8 and pulmonary hypertension. Emerging Infectious Diseases, 11, 1480-82.
95. Spiekerkoetter, E., Alvira, C.M., Kim, Y.M. et al. (2008) Reactivation of gammaHV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin. American Journal of Physiology: Lung Cellular and Molecular Physiology, 294, L276-89.
96. Marecki, J.C., Cool, C.D., Parr, J.E. et al. (2006) HIV-1 nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. American Journal of Respiratory and Critical Care Medicine, 174, 437-45.
97. Schermuly, R.T., Dony, E., Ghofrani, H.A. et al. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. The Journal ofClinical Investigation, 115, 2811-21.
98. Moreno-Vinasco, L., Gomberg-Maitland, M., Maitland, M.L. et al. (2008) Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiological Genomics, 33, 278-91.